Sequential Multiple Assignment Randomized Trial for Bipolar Depression (NCT06433635)
🩺 Plain-English Summary (8th-Grade Level)
This is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 and type 2 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram).
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- University of Alabama Birmingham — Birmingham, Alabama
- Steve Strakowski — Bloomington, Indiana
- John Hopkins — Baltimore, Maryland
- McLean Hospital — Belmont, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Nagy Youssef — Grand Rapids, Michigan
- University of New Mexico Health Sciences Center Albuquerque — Albuquerque, New Mexico
- New York University Grossman School of Medicine NYU — New York, New York
- Montefiore Medical Center and Albert Einstein College of Medicine — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Case Western Reserve University — Cleveland, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- University of Pittsburgh — Pittsburgh, Pennsylvania
- University of Texas at Austin — Austin, Texas
- UT Southwestern Medical Center — Dallas, Texas
- UT Health Houston Texas — Houston, Texas
- University of British Columbia — Vancouver, British Columbia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Bipolar I Disorder
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder — Boston, Massachusetts
- An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania — Little Rock, Arkansas
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder — Rochester, Minnesota
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder — Huntsville, Alabama
- Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder — Belmont, Massachusetts
Explore by condition: All Bipolar I Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.